LEIDEN, The Netherlands, May 25, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following investor conferences in the month of June:
Pharming's management will be available for one-to-one investor meetings during the Jefferies and Stifel conferences.
For more information about these conferences, or to schedule a one-to-one with Pharming's management team, please contact your Jefferies or Stifel representative, or send an email to Pharming's Investor Relations team to This email address is being protected from spambots. You need JavaScript enabled to view it..
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
Heather Robertson, Investor Relations & Corporate Communications Manager
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens T: +31 6 53 81 64 27 E: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$7.40 |
Daily Change: | -0.28 -3.65 |
Daily Volume: | 2,715 |
Market Cap: | US$502.020M |
August 09, 2023 June 01, 2023 April 11, 2023 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB